K
Kimio Ushijima
Researcher at Kurume University
Publications - 187
Citations - 3746
Kimio Ushijima is an academic researcher from Kurume University. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 26, co-authored 154 publications receiving 2790 citations. Previous affiliations of Kimio Ushijima include National Defense Medical College.
Papers
More filters
Journal ArticleDOI
Multicenter Phase II Study of Fertility-Sparing Treatment With Medroxyprogesterone Acetate for Endometrial Carcinoma and Atypical Hyperplasia in Young Women
Kimio Ushijima,Hideaki Yahata,Hiroyuki Yoshikawa,Ikuo Konishi,Toshiharu Yasugi,Toshiaki Saito,Toru Nakanishi,Hiroshi Sasaki,Fumitaka Saji,Tsuyoshi Iwasaka,Masayuki Hatae,Shoji Kodama,Tsuyoshi Saito,Naoki Terakawa,Nobuo Yaegashi,Masamichi Hiura,Atsuhiko Sakamoto,Hitoshi Tsuda,Masaharu Fukunaga,Toshiharu Kamura +19 more
TL;DR: The efficacy of fertility-sparing treatment with a high-dose of MPA for EC and AH was proven by this prospective trial, however, close follow-up is required because of the substantial rate of recurrence.
Journal ArticleDOI
Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Cisplatin in Metastatic or Recurrent Cervical Cancer: The Open-Label Randomized Phase III Trial JCOG0505
Ryo Kitagawa,Noriyuki Katsumata,Taro Shibata,Toshiharu Kamura,Takahiro Kasamatsu,Toru Nakanishi,Sadako Nishimura,Kimio Ushijima,Masashi Takano,Toyomi Satoh,Hiroyuki Yoshikawa +10 more
TL;DR: TC was noninferior to TP and should be a standard treatment option for metastatic or recurrent cervical cancer, however, cisplatin is still the key drug for patients who have not received platinum agents.
Journal ArticleDOI
Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer.
Vicky Makker,Nicoletta Colombo,Antonio Casado Herraez,Alessandro D. Santin,Emeline Colomba,Keiichi Fujiwara,Sandro Pignata,Sally Baron-Hay,Isabelle Ray-Coquard,Ronnie Shapira-Frommer,Kimio Ushijima,Jun Sakata,Kan Yonemori,Yong Man Kim,E M Guerra,Ulus Ali Sanli,Mary McCormack,Alan D Smith,Stephen Oʼ Keefe,Steven Bird,Lea Dutta,Robert J. Orlowski,Domenica Lorusso +22 more
TL;DR: Lenvatinib plus pembrolizumab led to significantly longer progression-free survival and overall survival than chemotherapy among patients with advanced endometrial cancer.
Journal ArticleDOI
Comparison of treatment invasiveness between upfront debulking surgery versus interval debulking surgery following neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and peritoneal cancers in a phase III randomised trial: Japan Clinical Oncology Group Study JCOG0602
Takashi Onda,Toyomi Satoh,Toshiaki Saito,Takahiro Kasamatsu,Toru Nakanishi,Kenichi Nakamura,Masashi Wakabayashi,Kazuhiro Takehara,Motoaki Saito,Kimio Ushijima,Hiroaki Kobayashi,Kei Kawana,Harushige Yokota,Masashi Takano,Nobuhiro Takeshima,Yoh Watanabe,Nobuo Yaegashi,Ikuo Konishi,Toshiharu Kamura,Hiroyuki Yoshikawa +19 more
TL;DR: The findings demonstrated that NAC treatment is less invasive than standard treatment and may become the new standard treatment for advanced ovarian cancer when non-inferior survival is confirmed in the planned primary analysis in 2017.
Journal ArticleDOI
High-Risk Ovarian Cancer Based on 126-Gene Expression Signature Is Uniquely Characterized by Downregulation of Antigen Presentation Pathway
Kosuke Yoshihara,Tatsuhiko Tsunoda,Daichi Shigemizu,Hiroyuki Fujiwara,Masayuki Hatae,Hisaya Fujiwara,Hideaki Masuzaki,Hidetaka Katabuchi,Yosuke Kawakami,Aikou Okamoto,Takayoshi Nogawa,Noriomi Matsumura,Yasuhiro Udagawa,Tsuyoshi Saito,Hiroaki Itamochi,Masashi Takano,Etsuko Miyagi,Tamotsu Sudo,Kimio Ushijima,Haruko Iwase,Hiroyuki Seki,Yasuhisa Terao,Takayuki Enomoto,Mikio Mikami,Kohei Akazawa,Hitoshi Tsuda,Takuya Moriya,Atsushi Tajima,Ituro Inoue,Kenichi Tanaka +29 more
TL;DR: Through gene ontology and pathway analyses, a significant reduction in expression of immune-response–related genes, especially on the antigen presentation pathway, in high-risk ovarian cancer patients is identified.